UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 9, 2024

Proto Labs, Inc.

(Exact name of registrant as specified in its charter)

	Minnesota	001-35435	41-1939628
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
	5540 Pioneer Creek Drive Maple Plain, Minnesota		55359
	(Address of principal executive offices)		(Zip Code)
	Registrant's telephone number, including area co	ode:	(763) 479-3680
		Not Applicable	
	(Former name	or former address, if changed sine	ce last report)
Securi	ties registered pursuant to Section 12(b) of the Act:		
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
			rame of each exchange on which registered
	Common Stock, Par Value \$0.001 Per Share	PRLB	New York Stock Exchange
	Common Stock, Par Value \$0.001 Per Share the appropriate box below if the Form 8-K filing is inting provisions:	PRLB	New York Stock Exchange
	the appropriate box below if the Form 8-K filing is int	PRLB ended to simultaneously satisfy th	New York Stock Exchange e filing obligation of the registrant under any of the
follow	the appropriate box below if the Form 8-K filing is inting provisions:	PRLB ended to simultaneously satisfy th the Securities Act (17 CFR 230.42	New York Stock Exchange e filing obligation of the registrant under any of the 25)
follow	the appropriate box below if the Form 8-K filing is inting provisions: Written communications pursuant to Rule 425 under	PRLB ended to simultaneously satisfy the the Securities Act (17 CFR 230.42). Exchange Act (17 CFR 240.14a-	New York Stock Exchange e filing obligation of the registrant under any of the 25)
follow	the appropriate box below if the Form 8-K filing is inting provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the	PRLB ended to simultaneously satisfy the the Securities Act (17 CFR 230.42). Exchange Act (17 CFR 240.14a-le 14d-2(b) under the Exchange Act.	New York Stock Exchange e filing obligation of the registrant under any of the 25) 12) et (17 CFR 240.14d-2(b))
follow Graph of the state of t	the appropriate box below if the Form 8-K filing is inting provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Rule Pre-comm	PRLB ended to simultaneously satisfy the the Securities Act (17 CFR 230.42). Exchange Act (17 CFR 240.14a-le 14d-2(b) under the Exchange Act (18 Exchange Act	New York Stock Exchange e filing obligation of the registrant under any of the 25) 12) et (17 CFR 240.14d-2(b))
follow Graph of the state of t	the appropriate box below if the Form 8-K filing is inting provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Rule Pre-commencement communications pursuant to Rule by check mark whether the registrant is an emerging	PRLB ended to simultaneously satisfy the the Securities Act (17 CFR 230.42). Exchange Act (17 CFR 240.14a-le 14d-2(b) under the Exchange Act (18 Exchange Act	New York Stock Exchange e filing obligation of the registrant under any of the 25) 12) et (17 CFR 240.14d-2(b)) et (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On February 9, 2024, Proto Labs, Inc. issued a press release announcing its fourth quarter and full year 2023 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 <u>Press release of Proto Labs, Inc. dated February 9, 2024</u>

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned	
nereunto duly authorized.	

Proto Labs, Inc.

Date: February 9, 2024 By: /s/ Daniel Schumacher

Daniel Schumacher Chief Financial Officer



3D Printing CNC Machining Sheet Metal Fabrication Injection Molding

Protolabs Reports Financial Results for the Fourth Quarter and Full Year 2023

Revenue of \$125 Million in the Fourth Quarter of 2023 Record Annual Revenue of \$504 Million in 2023

MINNEAPOLIS, Minn. – February 9, 2024 – Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights:

- Revenue was \$125.0 million, an 8.2% increase compared to the fourth quarter of 2022.
- Revenue generated from Protolabs Network was \$22.5 million, a 52.0% increase compared to the fourth quarter of 2022.
- Net income was \$7.0 million, or \$0.27 per diluted share, compared to a net loss of \$4.24 per diluted share in the fourth quarter of 2022.
- Non-GAAP net income was \$11.8 million, or \$0.46 per diluted share, compared to \$7.0 million, or \$0.26 per diluted share, in the fourth quarter of 2022. See "Non-GAAP Financial Measures" below.
- EBITDA was \$18.3 million, or 14.6% of revenue. See "Non-GAAP Financial Measures" below.
- Adjusted EBITDA was \$22.3 million, or 17.8% of revenue, compared to \$14.5 million, or 12.5% of revenue, in the fourth quarter of 2022. See
 "Non-GAAP Financial Measures" below.

Full Year 2023 Financial Highlights:

- Revenue was a record \$503.9 million, representing a 3.2% increase over 2022.
- Revenue generated from Protolabs Network was \$82.6 million in 2023, representing growth of 70.4% over the prior year.
- Net income was \$17.2 million, or \$0.66 per diluted share, compared to a net loss of \$3.77 per diluted share in 2022.
- Non-GAAP net income was \$41.6 million, or \$1.59 per diluted share, compared to \$41.1 million, or \$1.50 per diluted share, in 2022. See "Non-GAAP Financial Measures" below.
- EBITDA was \$63.2 million, or 12.6% of revenue, in 2023. See "Non-GAAP Financial Measures" below.
- Adjusted EBITDA was \$83.2 million, or 16.5% of revenue, in 2023. See "Non-GAAP Financial Measures" below.
- Cash flow from operations was \$73.3 million in 2023, compared to \$62.1 million in 2022.
- The Company repurchased \$44.0 million in common shares during the year.
- Protolabs served 53,464 customer contacts during the year.

"We capped off a record year with strong fourth quarter results, driven by consistent execution against our priorities," said Rob Bodor, President and Chief Executive Officer. "For the full year, we generated revenue above \$500 million for the first time in our 25-year history, while delivering improved earnings, robust cash flow, and substantial capital returned to shareholders. We are encouraged by our strong finish to 2023, and we believe we have the right strategy and priorities in place to continue our momentum throughout 2024. We remain focused on driving positive global impact, maintaining our industry-leading financial model, and increasing value for our shareholders."

Dan Schumacher, Chief Financial Officer, commented, "Along with record revenue in 2023, we significantly improved profitability in both the digital factory and the digital network. We generated an industry-leading \$73 million in cash from operations, and we paid 97% of our free cash flows to shareholders through share repurchases."

First Quarter 2024 Outlook

The Company will continue to provide financial guidance on a quarterly basis due to the quick-turn nature of the business and continued uncertainty in global manufacturing.

For the first quarter of 2024, the Company expects to generate revenue between \$120 million and \$128 million. This guidance reflects a softer start to 2024, due to December 2023 and early January 2024 order levels being lower than historical periods. However, recent performance has been more in line with historical trends, and our guidance assumes that will continue through the end of March.

The Company expects first quarter 2024 diluted net income per share between \$0.09 and \$0.17, and non-GAAP diluted net income per share between \$0.26 and \$0.34. See "Non-GAAP Financial Measures" below.

Non-GAAP Financial Measures

The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, "non-GAAP revenue growth"). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.

The Company has included earnings before interest, taxes, depreciation and amortization ("EBITDA") and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency, goodwill impairment and costs related to the Japan closure activities (collectively, "Adjusted EBITDA"), in this press release to provide investors with additional information regarding the Company's financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin ("EBITDA margin") and EBITDA margin, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency, goodwill impairment and costs related to the Japan closure activities (collectively, "Adjusted EBITDA margin"), in this press release to provide investors with additional information regarding the Company's financial results.

The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense in this press release to provide investors with additional information regarding the Company's financial results.

The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense, goodwill impairment and costs related to the closure of Japan (collectively, "non-GAAP operating margin"), in this press release to provide investors with additional information regarding the Company's financial results.

The Company has included non-GAAP gross margin excluding Japan, adjusted for stock-based compensation expense and amortization expense in this press release to provide investors with additional information regarding the Company's financial results. The Company has included non-GAAP operating margin excluding Japan, adjusted for stock-based compensation expense, amortization expense, goodwill impairment and costs related to the Japan closure activities (collectively, "non-GAAP operating margin excluding Japan"), in this press release to provide investors with additional information regarding the Company's financial results.

The Company has included non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, goodwill impairment and costs related to the closure of Japan (collectively, "non-GAAP net income"), in this press release to provide investors with additional information regarding the Company's financial results.

The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP gross margin, non-GAAP gross margin excluding Japan, non-GAAP operating margin, non-GAAP operating margin excluding Japan, non-GAAP revenue growth by region and by service, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company's management and board of directors to understand and evaluate operating performance and trends and provide useful measures for period-to-period comparisons of the Company's business. Accordingly, the Company believes that

these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors.

Conference Call

The Company has scheduled a conference call to discuss its fourth quarter and full year 2023 financial results and first quarter 2024 outlook today, February 9, 2024 at 8:30 a.m. EST. To access the call in the U.S. please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EST start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/vyeizwtx/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.

About Protolabs

Protolabs is the fastest and most comprehensive digital manufacturing service in the world. Our digital factories produce low-volume parts in days while Protolabs Network unlocks advanced capabilities and volume pricing through its highly vetted manufacturing partners. The result? One manufacturing source—from prototyping to production—for product developers, engineers, and supply chain teams across the globe. See what's next at protolabs.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical or current facts are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the "Risk Factors" section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs' future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances. Source: Proto Labs, Inc.

Investor Relations Contacts

Protolabs Ryan Johnsrud, 612-225-4873 Manager – Investor Relations and FP&A ryan.johnsrud@protolabs.com

Gateway Group, Inc. 949-574-3860 PRLB@gateway-grp.com

Media Contact

Protolabs
Brent Renneke, 763-479-7704
Marketing Communications Manager
brent.renneke@protolabs.com

Proto Labs, Inc. Condensed Consolidated Balance Sheets (In thousands)

	Decembe 2023		December 31, 2022
	(Unaudi	ted)	
Assets			
Current assets			
Cash and cash equivalents	\$	83,790 \$	56,558
Short-term marketable securities		19,013	23,568
Accounts receivable, net		72,848	76,225
Inventory		13,657	13,578
Income taxes receivable		2,228	4,042
Prepaid expenses and other current assets		9,124	12,597
Total current assets		200,660	186,568
Property and equipment, net		253,655	257,785
Goodwill		273,991	273,991
Other intangible assets, net		25,584	31,250
Long-term marketable securities		8,019	26,419
Operating lease assets		4,628	3,844
Finance lease assets		960	17,532
Other long-term assets		4,856	4,779
Total assets	\$	772,353 \$	802,168
Liabilities and shareholders' equity			
Current liabilities			
Accounts payable	\$	15,636 \$	17,356
Accrued compensation		15,292	12,743
Accrued liabilities and other		16,872	22,384
Current operating lease liabilities		1,585	1,561
Current finance lease liabilities		296	17,537
Total current liabilities		49,681	71,581
Long-term operating lease liabilities		3,008	2,255
Long-term finance lease liabilities		595	_
Long-term deferred tax liabilities		18,742	26,322
Other long-term liabilities		5,032	4,362
Shareholders' equity		695,295	697,648
Total liabilities and shareholders' equity		772.353 \$	802.168

Proto Labs, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited)

		Three Mo Decen		Twelve Mo Decem	
		2023	2022	 2023	2022
Revenue					
Injection Molding	\$	51,486	\$ 44,885	\$ 203,941	\$ 200,578
CNC Machining		48,905	46,563	198,222	188,372
3D Printing		20,339	19,530	84,291	78,988
Sheet Metal		4,062	4,432	16,540	19,498
Other Revenue		256	197	883	962
Total Revenue		125,048	115,607	503,877	488,398
Cost of revenue		69,236	67,000	281,884	272,933
Gross profit		55,812	48,607	221,993	215,465
Operating expenses					
Marketing and sales		21,825	20,517	87,688	82,752
Research and development		9,488	8,906	40,135	38,222
General and administrative		16,075	17,774	65,788	67,544
Goodwill impairment		_	118,008	_	118,008
Closure of Japan business		29	534	215	6,922
Total operating expenses		47,417	165,739	193,826	313,448
Income (loss) from operations	·	8,395	(117,132)	28,167	(97,983)
Other income (loss), net		1,543	429	(215)	106
Income (loss) before income taxes	·	9,938	(116,703)	27,952	(97,877)
Provision for income taxes		2,948	(1,638)	10,732	5,585
Net income (loss)	\$	6,990	\$ (115,065)	\$ 17,220	\$ (103,462)
Net income (loss) per share:					
Basic	\$	0.27	\$ (4.24)	\$ 0.66	\$ (3.77)
Diluted	\$	0.27	\$ (4.24)	\$ 0.66	\$ (3.77)
Shares used to compute net income (loss) per share:					
Basic		25,820,802	27,136,821	26,186,533	27,409,838
Diluted		25,889,004	27,136,821	26,223,498	27,409,838

Proto Labs, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited)

			Twelve Months Ended December 31,			
		2023		2022		
Operating activities						
Net income (loss)	\$	17,220	\$	(103,462)		
Adjustments to reconcile net income (loss) to net cash provided by operating activities:						
Depreciation and amortization		37,528		39,425		
Stock-based compensation expense		15,989		17,545		
Deferred taxes		(7,656)		(9,499)		
Interest on finance lease obligations		1,055		_		
Loss on impairment of goodwill		_		118,008		
Loss on foreign currency translation		3,906		_		
Impairments related to closure of Japan business		_		2,842		
Gain on disposal of property and equipment		(498)		(1,211)		
Other		154		35		
Changes in operating assets and liabilities		5,576		(1,604)		
Net cash provided by operating activities		73,274		62,079		
Turnetine authita						
Investing activities Dividence of property equipment and other conits leggets		(20 116)		(21 696)		
Purchases of property, equipment and other capital assets		(28,116) 699		(21,686)		
Proceeds from sales of property, equipment and other capital assets Purchases of marketable securities		099		4,108 (46,872)		
Purchases of other assets and investments		(1,000)		(40,872)		
Proceeds from sales of marketable securities		(1,000)		1,998		
Proceeds from call redemptions and maturities of marketable securities		23,865		19,360		
Net cash used in investing activities		(4,552)		(43,092)		
1 for each used in investing activities		(1,332)		(13,072)		
Financing activities						
Proceeds from exercises of stock options		3,835		3,950		
Purchases of shares withheld for tax obligations		(1,436)		(1,682)		
Repurchases of common stock		(43,951)		(29,659)		
Principal repayments of finance lease obligations		(306)		(531)		
Net cash used in financing activities	·	(41,858)		(27,922)		
Effect of exchange rate changes on cash and cash equivalents		368		(436)		
Net increase (decrease) in cash and cash equivalents		27,232		(9,371)		
Cash and cash equivalents, beginning of period		56,558		65,929		
Cash and cash equivalents, end of period	\$	83,790	\$	56,558		

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Net Income per Share (In thousands, except share and per share amounts) (Unaudited)

	Three Moi Decem	 	Twelve Mo Decen	
	2023	2022	2023	2022
Non-GAAP net income (loss), adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, goodwill impairment and costs related to Japan closure activities				
GAAP net income (loss)	\$ 6,990	\$ (115,065)	\$ 17,220	\$ (103,462)
Add back:				
Stock-based compensation expense	4,178	4,210	15,989	17,545
Amortization expense	1,457	1,514	5,928	6,096
Unrealized (gain) loss on foreign currency	(211)	(490)	(125)	252
Goodwill impairment	_	118,008	_	118,008
Costs related to Japan closure activities	29	534	4,122	6,922
Total adjustments ¹	5,453	123,776	25,914	148,823
Income tax benefits on adjustments ²	(609)	(1,753)	(1,540)	(4,271)
Non-GAAP net income	\$ 11,834	\$ 6,958	\$ 41,594	\$ 41,090
Non-GAAP net income per share:				
Basic	\$ 0.46	\$ 0.26	\$ 1.59	\$ 1.50
Diluted	\$ 0.46	\$ 0.26	\$ 1.59	\$ 1.50
Shares used to compute non-GAAP net income per share:				
Basic	25,820,802	27,136,821	26,186,533	27,409,838
Diluted	25,889,004	27,151,991	26,223,498	27,433,257

¹ Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, goodwill impairment and costs related to Japan closure activities were included in the following GAAP consolidated statement of operations categories:

		Three Mo Decem			Twelve Months Ended December 31,			
	2023			2022	2023	2022		
Cost of revenue	\$	794	\$	840	\$ 3,210	\$	3,541	
Marketing and sales		916		816	3,424		3,295	
Research and development		669		488	2,557		2,190	
General and administrative		3,256		3,580	12,727		14,615	
Goodwill impairment		-		118,008	-		118,008	
Closure of Japan business		29		534	215		6,922	
Total operating expenses		4,870		123,426	18,923		145,030	
Other income (loss), net		(211)		(490)	3,781		252	
Total adjustments	\$	5,453	\$	123,776	\$ 25,914	\$	148,823	

² For the three and twelve months ended December 31, 2023 and 2022, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter.

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin (In thousands) (Unaudited)

	Three Mor Decem	 	Twelve Mo Decem	nths Ended ber 31,		
	 2023	2022	2023		2022	
Revenue	\$ 125,048	\$ 115,607	\$ 503,877	\$	488,398	
Gross profit	55,812	48,607	221,993		215,465	
GAAP gross margin	 44.6 %	42.0 %	44.1 %		44.1 %	
Add back:						
Stock-based compensation expense	452	498	1,840		2,172	
Amortization expense	342	342	1,370		1,369	
Total adjustments	 794	840	3,210		3,541	
Non-GAAP gross profit	\$ 56,606	\$ 49,447	\$ 225,203	\$	219,006	
Non-GAAP gross margin	 45.3 %	42.8 %	44.7 %		44.8 %	

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin Excluding Japan (In thousands) (Unaudited)

	Three Mo Decen	 	Twelve Months Ended December 31,					
	 2023	2022	2023		2022			
Revenue	\$ 125,048	\$ 115,607	\$ 503,877	\$	488,398			
Revenue excluding Japan	\$ 125,048	\$ 115,607	\$ 503,877	\$	480,169			
Gross profit	55,812	48,607	221,993		215,465			
GAAP gross margin	 44.6 %	42.0 %	44.1 %	·	44.1 %			
Less: Japan gross profit	_	(93)	_		3,057			
Gross Profit excluding Japan	 55,812	48,700	221,993		212,408			
GAAP gross margin excluding Japan	44.6 %	42.1 %	44.1 %)	44.2 %			
Add back:								
Stock-based compensation expense	452	498	1,840		2,172			
Amortization expense	342	342	1,370		1,369			
Less:								
Japan stock-based compensation expense	_		_		61			
Japan amortization expense	_	_	_		_			
Total adjustments	 794	 840	 3,210		3,480			
Non-GAAP gross profit excluding Japan	\$ 56,606	\$ 49,540	\$ 225,203	\$	215,888			
Non-GAAP gross margin excluding Japan	 45.3 %	42.9 %	 44.7 %)	45.0 %			

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Operating Margin (In thousands) (Unaudited)

		Three Mo Decen			Twelve Months Ended December 31,						
	2023			2022		2023	2022				
Revenue	\$	125,048	\$	115,607	\$	503,877	\$	488,398			
Income (loss) from operations		8,395		(117,132)		28,167		(97,983)			
GAAP operating margin		6.7 %		(101.3 %)		5.6 %		(20.1 %)			
Add back:											
Stock-based compensation expense		4,178		4,210		15,989		17,545			
Amortization expense		1,457		1,514		5,928		6,096			
Goodwill impairment		_		118,008		_		118,008			
Costs related to Japan closure activities		29		534		215		6,922			
Total adjustments		5,664		124,266		22,132		148,571			
Non-GAAP income from operations	\$	14,059	\$	7,134	\$	50,299	\$	50,588			
Non-GAAP operating margin		11.2 %	6.2 %		10.0 %			10.4 %			

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Operating Margin Excluding Japan (In thousands) (Unaudited)

	Three Mo Decen	 		Twelve Months Ended December 31,					
	2023	2022		2023		2022			
Revenue \$	125,048	\$ 115,607	\$	503,877	\$	488,398			
Revenue excluding Japan \$	125,048	\$ 115,607	\$	503,877	\$	480,169			
Income (loss) from operations	8,395	(117,132)		28,167		(97,983)			
GAAP operating margin	6.7 %	(101.3 %	<u>)</u>	5.6 %	, D	(20.1 %)			
Less: Japan (loss) income from operations	(18)	(594)		(499)		(1,424)			
Income from operations excluding Japan	8,413	(116,538)		28,666		(96,559)			
GAAP operating margin excluding Japan	6.7 %	(100.8 %	o)	5.7 %	, D	(20.1 %)			
Add back:									
Stock-based compensation expense	4,178	4,210		15,989		17,545			
Amortization expense	1,457	1,514		5,928		6,096			
Goodwill impairment	_	118,008		_		118,008			
Costs related to Japan closure activities	29	534		215		6,922			
Less:									
Japan stock-based compensation expense	_	20		17		406			
Japan amortization expense	_	_		_		_			
Total adjustments	5,664	124,246		22,115		148,165			
Non-GAAP income from operations excluding Japan \$	14,077	\$ 7,708	\$	50,781	\$	51,606			
Non-GAAP operating margin excluding Japan	11.3 %	6.7 %)	10.1 %	, D	10.7 %			

Proto Labs, Inc. Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDA (In thousands) (Unaudited)

	Three Mo Dece				Twelve Months Ended December 31,			
	 2023		2022		2023		2022	
Revenue	\$ 125,048	\$	115,607	\$	503,877	\$	488,398	
GAAP net income (loss)	6,990		(115,065)		17,220		(103,462)	
GAAP net income margin	5.6 %)	(99.5 %))	3.4 %	, 0	(21.2 %)	
Add back:								
Amortization expense	\$ 1,457	\$	1,514	\$	5,928	\$	6,096	
Depreciation expense	7,858		7,930		31,600		33,329	
Interest income, net	(951)		(509)		(2,234)		(968)	
Provision for income taxes	2,948		(1,638)		10,732		5,585	
EBITDA	18,302		(107,768)		63,246		(59,420)	
EBITDA Margin	 14.6 %)	(93.2 %))	12.6 %	, D	(12.2 %)	
Add back:								
Stock-based compensation expense	4,178		4,210		15,989		17,545	
Unrealized (gain) loss on foreign currency	(211)		(490)		(125)		252	
Goodwill impairment	<u> </u>		118,008		· <u> </u>		118,008	
Costs related to Japan closure activities	29		534		4,122		6,922	
Total adjustments	3,996		122,262		19,986		142,727	
Adjusted EBITDA	\$ 22,298	\$	14,494	\$	83,232	\$	83,307	
Adjusted EBITDA Margin	 17.8 %	,	12.5 %		16.5 %	, o	17.1 %	

Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Region (In thousands) (Unaudited)

	Three Months Ended December 31, 2023						Three Months Ended December 31, 2022		
	GAAP		Foreign Currency ¹	N	Non-GAAP		GAAP	% Change²	% Change Organic ³
Revenues									
United States	\$ 98,814	\$	_	\$	98,814	\$	92,278	7.1 %	7.1 %
Europe	26,234		(1,144)		25,090		23,329	12.5 %	7.5 %
Total revenue	\$ 125,048	\$	(1,144)	\$	123,904	\$	115,607	8.2 %	7.2 %

	 Twelve Months Ended December 31, 2023						Twelve Months Ended December 31, 2022		
	GAAP	(Foreign Currency ¹		Non-GAAP		GAAP	% Change²	% Change Organic ³
Revenues									
United States	\$ 396,821	\$	_	\$	396,821	\$	387,399	2.4 %	2.4 %
Europe	107,056		167		107,223		92,770	15.4 %	15.6 %
Japan	_		_		_		8,229	(100.0 %)	(100.0 %)
Total revenue	\$ 503,877	\$	167	\$	504,044	\$	488,398	3.2 %	3.2 %

- 1 Revenue for the three and twelve months ended December 31, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
- 2 This column presents the percentage change from GAAP revenue for the three and twelve months ended December 31, 2022 to GAAP revenue for the twelve months ended months ended December 31, 2023.
- 3 This column presents the percentage change from GAAP revenue for the three and twelve months ended December 31, 2022 to non-GAAP revenue for the three and twelve months ended December 31, 2023 (as recalculated using the foreign currency exchange rates in effect during the three and twelve months ended December 31, 2022) in order to provide a constant-currency comparison.

Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Service Line (In thousands) (Unaudited)

	 	 e Months Ende ember 31, 2023	 [Three Months Ended December 31, 2022		
	GAAP	Foreign Currency ¹	Non-GAAP	GAAP	% Change²	% Change Organic ³
Revenues						
Injection Molding	\$ 51,486	\$ (453)	\$ 51,033	\$ 44,885	14.7 %	13.7 %
CNC Machining	48,905	(395)	48,510	46,563	5.0	4.2
3D Printing	20,339	(268)	20,071	19,530	4.1	2.8
Sheet Metal	4,062	(1)	4,061	4,432	(8.3)	(8.4)
Other Revenue	256	(27)	229	197	29.9	16.2
Total Revenue	\$ 125,048	\$ (1,144)	\$ 123,904	\$ 115,607	8.2 %	7.2 %

	Twelve Months Ended December 31, 2023							Twelve Months Ended December 31, 2022		
		GAAP	Foreign Currency ¹ Non-G.		Non-GAAP		GAAP	% Change²	% Change Organic ³	
Revenues										
Injection Molding	\$	203,941	\$	328	\$	204,269	\$	200,578	1.7 %	1.8 %
CNC Machining		198,222		(243)		197,979		188,372	5.2	5.1
3D Printing		84,291		9		84,300		78,988	6.7	6.7
Sheet Metal		16,540		(10)		16,530		19,498	(15.2)	(15.2)
Other Revenue		883		83		966		962	(8.2)	0.4
Total Revenue	\$	503,877	\$	167	\$	504,044	\$	488,398	3.2 %	3.2 %

¹ Revenue for the three and twelve months ended December 31, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

² This column presents the percentage change from GAAP revenue for the three and twelve months ended December 31, 2022 to GAAP revenue for the three and twelve months ended December 31, 2023.

³ This column presents the percentage change from GAAP revenue for the three and twelve months ended December 31, 2022 to non-GAAP revenue for the three and twelve months ended December 31, 2023 (as recalculated using the foreign currency exchange rates in effect during the three and twelve months ended December 31, 2022) in order to provide a constant-currency comparison.

Proto Labs, Inc. Customer Contact Information (Unaudited)

	Three Months I December 3		Twelve Months Ended December 31,		
	 2023	2022	2023	2022	
Customer contacts	21,879	22,205	53,464	56,333	
Revenue per customer contact	\$ 5,715 \$	5,206	\$ 9,425 \$	8,670	

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Guidance (In thousands, except per share and per share amounts) (Unaudited)

		Q1 2024 Outlook
	Lo	w High
GAAP diluted net income per share	\$	0.09 0.17
Add back:		
Stock-based compensation expense		0.14 0.14
Amortization expense		0.03 0.03
Unrealized (gain) loss on foreign currency		0.00
Total adjustments		0.18 0.18
Non-GAAP diluted net income per share	\$	0.26 \$ 0.34